Literatur
- 1 Appelman H D, Goldman H, Appelman H D. et al .Mesenchymal tumours of the gut: historical
perspectives, new
approaches, new results, and does it make any
difference?. Baltimore: Williams and Wilkins In:
Gastrointestinal
pathology 1990: 220-246
- 2
Chan J KC.
Mesenchymal tumours of the gastrointestinal tract: a paradise
for acronyms (STUMP, GIST, GANT and now GIPACT). Implications of c-kit in
genesis, and yet another of many emerging roles of the interstitial cell of
Cajal in the pathogenesis of gastrointestinal disease.
Anat
Pathol.
1999;
6
19-40
- 3
De Matteo R P, Lewis J J, Leung D. et al .
Two hundred gastrointestinal stromal tumors. Recurrence
patterns and prognostic factors for survival.
Ann
Surg.
2000;
23
51-58
- 4
Demetri G D, von Mehren M, Blanke C D. et al .
Efficacy and safety of imatinib mesylate in advanced
gastrointestinal stromal tumors.
N Engl J
Med.
2002;
347
472-480
- 5
Joensuu H.
Treatment of GIST with Imatinib.
Med
Klin.
2001;
96
1-3
(Suppl
II)
- 6
Joensuu H, Roberts P J, Sarlomo-Rikala M. et al .
Effect of the tyrosine kinase inhibitor STI571 in a patient
with a metastatic gastrointestinal stromal tumor.
N Engl J
Med.
2001;
322
1052-1056
- 7
Kindblom L G, Remotti H E, Aldenborg F, Meis-Kindblom M.
Gastrointestinal pacemaker cell tumor (GIPACT).
Gastrointestinal stromal tumors show phenotypic characteristics of the
interstitial cells of c ajal.
Am J Clin
Pathol.
1998;
152
1259-1269
- 8
Palazzo L, Landi B, Cellier C, Cuillerier E, Roseau G, Barbier J P.
Endosonographic features predictive of benign and malignant
gastrointestinal stromal cell
tumours.
Gut.
2000;
46
88-92
- 9
Perez-Atayde A R, Shamberger R C, Kozakewich H W.
Neuroectodermal differentiation of the gastrointestinal
tumors in the Carney triad. An ultrastructural and immunohistochemical
study.
Am J Surg
Pathol.
1993;
17
706-714
- 10
Sarlomo-Rikala M, Kovatich A J, Barusevicius A, Miettinen M.
CD117: a sensitive marker for gastrointestinal stromal tumors
that is more specific than CD34.
Mod
Pathol.
1998;
11
728-734
- 11
Van Oosterom A T, Judson I, Verweij J. et al .
Safety and efficacy of Imatinib (STI571) in metastatic
gastrointestinal stromal tumours: a phase I
study.
Lancet.
2001;
358
1421-1423
- 12
Van Oosterom A T, Judson I, Verweij J. et al .
Update of the imatinib (STI571, Glivec) phase I study in
gastrointestinal stromal tumours (GISTs).
Proc Am Soc Clin
Oncol.
2002;
21
327
Prof. Dr. J. F. Riemann
Medizinische Klinik C, Klinikum der Stadt Ludwigshafen gGmbH
Bremserstraße 79
67063 Ludwigshafen am Rhein
Telefon: 0621/503-4100
Fax: 0621/503-4114
eMail: MedCLu@t-online.de
